SCHEMBL9974099

SCHEMBL9974099

O=C(COc1ccc2cccnc2c1)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
ALDH1A1 P00352 3/20 0.62
MAPT P10636 2/20 0.62
PKM P14618 4/20 0.61
SCN3A Q9NY46 1/20 0.57
NPC1 O15118 1/20 0.57
NFKB1 P19838 1/20 0.57
RAB9A P51151 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
LMNA P02545 1/20 0.56
TSHR P16473 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
P2RY14 Q15391 2/20 0.54
RXFP1 Q9HBX9 2/20 0.54
RECQL P46063 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9974108 0.93 PKM (0.61) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL15116271 0.91 MEN1 (0.72) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL9974106 0.90 MEN1 (0.61) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL9974104 0.84 PKM (0.60) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL1102271 0.84 MEN1 (0.60) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL15116296 0.83 PKM (0.74) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL9974107 0.83 PKM (0.66) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL9972179 0.83 PKM (0.57) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL15116285 0.83 PKM (0.63) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL15113358 0.83 PKM (0.71) MEN1KMT2AALDH1A1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309543-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-13 US disclosed
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 US disclosed
US-8202861-B2 Drugs for various disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS SCNN1G, KCNN3, KCNN2 MEN1 2329/4885KMT2A 3111/4885ALDH1A1 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.